PROVETOP

Biotinylated Human CD44v9 Protein

Catalog No: CD44V9-HB001

Species
Human
Expression System
HEK293
Tag
His, Avi
Activity
Activity verified

Product overview

Recombinant Biotinylated Human CD44v9 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Gln21-Pro220 & Gln506-Ser534 (UniProt accession: P16070-1).

Product Details

Molecular Aliases
CD44; CDw44; Epican; ECMR-III; LHR; MDU2; MDU3; MIC4; PGP-I; CSPG8; HCELL; HUTCH-I; IN; MC56
Protein Length
Gln21-Pro220
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 28.13 kDa. Due to glycosylation, the protein migrates to 45-65 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
State
Liquid
Storage Conditions
Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Data Display

Bis-Tris PAGE
CD44V9-HB001 Bis-Tris-PAGE-white result

Biotinylated Human CD44v9 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
CD44V9-HB001 SEC-HPLC result

The purity of Biotinylated Human CD44v9 is greater than 95% as determined by SEC-HPLC.

ELISA
CD44V9-HB001 ELISA result

Immobilized Biotinylated Human CD44v9, His Avi tag at 0.5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-CD44v9 Antibody, hFc Tag with the EC50 of 6.2ng/ml determined by ELISA. (QC Test)

Background

CD44 is a hyaluronan binding cell surface signal transducing receptor that influences motility, cell survival and proliferation as well as the formation of tumor microenvironment. CD44 contains two variable regions encoded by variable exons. Alternative splicing, which is often deregulated in cancer, can produce various isoforms of CD44 with properties that may have different tissue specific effects and therefore even diverse effects on cancer progression

References

  1. Prochazka L, Tesarik R, Turanek J. Regulation of alternative splicing of CD44 in cancer. Cell Signal. 2014 Oct;26(10):2234-9. doi: 10.1016/j.cellsig.2014.07.011. Epub 2014 Jul 13. PMID: 25025570.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support